In vivo, we developed a novel syngeneic Syrian hamster model for renal cancer, and TILT-517+anti-PD-L1 group presented significant enhanced tumor growth control and led to an increased number of effector and antigen-presenting cells compared to anti-PD-L1 monotherapy. Here, CD274 is linked to renal carcinoma.